Improving Patient Adherence and Quality of Life in Managing B-Cell Malignancies with BTK Inhibitors: Strategies for Anticipating, Recognizing, and Managing Adverse Events

A continuing medical education activity sponsored by NAMCP and AAMCN.

Expert Perspectives on the Role of BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): What Managed Care Needs to Know for Improved Clinical and Economic Outcomes is a 3-part live webinar series that
will provide attendees with the latest information in the management of CLL

This is Part 2 of the series focusing on anticipating, recognizing, and managing adverse events

This activity is an archive from the webinar held April 3, 2020

This activity is valid from May 1, 2020 to May 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Bruton's tyrosine kinase (BTK) is an enzyme that in humans is encoded by the BTK gene. BTK is abundantly expressed and constitutively active in the pathogenesis of B cell hematological malignancies. Therefore, BTK is considered as an attractive target for treatment of B-cell malignancies. These options, known as BTK inhibitors, have changed the treatment paradigm in several different B-cell malignancies in recent years. These agents differ in dosing, efficacy, and toxicities, and as these options for B-cell malignancies grow, it is essential to understand their clinical and economic role in the treatment paradigm to offer patients the safest and most efficacious treatment, while also controlling costs.

Upon completion of this activity, participants will be able to:

  • Compare BTK inhibitors in B-Cell malignancies, with a focus on CLL, including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use

  • Discuss strategies to mitigate and manage predictable toxicities that have been reported with the use of BTK inhibitors in B-Cell malignancies, with a focus on CLL

  • Discuss methods to communicate effectively with cancer patients and the multidisciplinary team to understand and address the needs of each patient around BTK inhibitors and improve treatment adherence, quality of life, and survival outcomes

  • Review how treatment strategies can be affected by adverse events based on patient’s individualized needs

Faculty: Matthew Davids, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Associate. Director, CLL Center
Dana-Farber Cancer Institute


Dr. Davids serves on an advisory board for AbbVie, Ascentage Pharma, Astra-Zeneca, Celgene, Genentech, Janssen, Pharmacyclics, and TG Therapeutics. He serves as a consultant for AbbVie, Adaptive Biotechnologies, Astra-Zeneca, BeiGene, Genentech, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, and Verastem. He has received grants or research from Ascentage Pharma, Astra-Zeneca, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue